Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Mylotarg in first complete remission AML patients undergoing autologous hematopoietic stem cell transplant
2005-000640-91Phase 2Active
- Sponsor
- Hospital de la Santa Creu i Sant Pau Research Institute
- Start
- May 2006
- Modality
- Cytotoxic ADCs → Antibody-Drug Conjugates (ADCs) → Antibody Conjugates → Antibody-Based Therapeutics, Monoclonal Antibodies → Antibody-Based Therapeutics, Small Molecules
- Countries
- 1
01
Overview
Phase 2, single-arm trial of gemtuzumab ozogamicin in acute myeloid leukemia (AML), sponsored by Hospital de la Santa Creu i Sant Pau Research Institute. Primary endpoints: Leukemia relapse frequency and Immediate toxicity of Mylotarg. Started May 2006; status: active.
02
Drugs
gemtuzumab ozogamicin
03
Conditions
acute myeloid leukemia (AML)
Beyond the preview
Go deeper on 2005-000640-91.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2005-000640-91.